Osiris: Ex-U.S. biotech executive fined for lying to auditors, charges dropped against CFO: SEC

The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a $40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday.